Aditxt Inc. Subsidiary Pearsanta Engages Spartan Capital for Planned IPO to Advance Cancer Detection
Aditxt Inc.'s subsidiary Pearsanta, Inc. has taken a significant step towards its Initial Public Offering by appointing Spartan Capital Securities, LLC as the lead underwriter, aiming to enhance early cancer and disease detection technologies.
Aditxt Inc. (NASDAQ: ADTX) has announced that its subsidiary, Pearsanta, Inc., has engaged Spartan Capital Securities, LLC as the lead underwriter for its planned Initial Public Offering (IPO). This strategic move is designed to bolster the clinical validation and commercial deployment of Pearsanta's innovative early cancer and disease detection tests. These tests are powered by the Mitomic mitochondrial DNA platform and supported by a CLIA-certified, CAP-accredited laboratory infrastructure.
Amro Albanna, CEO of Aditxt, highlighted that the IPO is a key component of the company's Acquire, Build, and Capitalize strategy. This approach is intended to expand Pearsanta's market access and facilitate the delivery of life-saving diagnostics through early detection. The initiative underscores Aditxt's commitment to accelerating health innovations and addressing significant societal challenges through its unique innovation platform.
For further details on this development, visit https://ibn.fm/npyvx.